news
2008 news archive
28.10.08
GBL in China - Collaboration Agreement
Collaboration between Energy Research Institute of Shandong Academy of Sciences (SDERI), China and Green Biologics Ltd. (GBL), UK
14th October 2008,
SDERI is engaged in a number of technical solutions in the area of renewable energy and biomass gasification. Shandong is one of the most prosperous Chinese provinces with large agricultural, energy and trading economies.
18.09.08
Green Biologics is selected for Cleantech 100 Award
Green Biologics Ltd has been listed in the prestigious Cleantech 100 Awards compiled by Library House, a leading technology ventures and investors research organisation. The listing comes as GBL’s Chief Executive, Sean Sutcliffe, announced the launch of a £3.5 million fundraising round as GBL rolls out its technology to global markets. As part of this roll-out, GBL also announces the signing of an agreement between GBL and Laxmi Organic Industries to develop and construct a commercial scale demonstrator for biobutanol in India. Laxmi Organic Industries is a leading Indian biochemicals manufacturer that ranks among the world’s top 10 producers of ethyl acetate.
CEO of GBL, Sean Sutcliffe, said: “We are honoured to receive this Award and delighted that it recognises the substantial impact Green Biologics can have on the global biochemicals and advanced biofuels sector through the adoption of our unique technology for the conversion of by-products and waste feedstocks to butanol.
“This Award comes at a particularly interesting time for GBL as we take a major step forward in the commercialisation of our technology with the successful conclusion of our agreement with Laxmi Organic Industries. We will be working with Laxmi to develop and build a commercial demonstrator plant in Mumbai that will be run on molasses, a sustainable by-product from the Indian sugar industry, and produce 1,000 tonnes of butanol per annum. We are aiming to have the plant fully operational in 2010.”
06.05.08
Green Biologics announces new Management Team appointments
GBL today announces the appointment of Sean Sutcliffe as Chief Executive and Kristan Wadrop as Chief Operating Officer with immediate effect. Mr Sutcliffe succeeds founder and former CEO, Dr Edward Green, who becomes Chief Technical Officer.
Mr Sutcliffe, 44, joins GBL from Biofuels Corporation Trading Ltd, which operates one of Europe’s largest biodiesel plants, where he has been Chief Executive since 2005 and will retain a non-executive Chairman position. Mr Wadrop, 36, joins from Vireol plc, where he was responsible for technical and operational delivery including the project management of a £150 million bio-ethanol plant.
Dr Edward Green comments “Sean and Kris bring considerable experience from first generation biofuel production. These appointments will speed up the transition of our proprietary bio-butanol technology from lab to pilot demonstration and commercialisation”
11.02.08
Fermentation Pilot Plant
GBL has installed and commissioned a Fermentation Pilot Plant at its facilities on Milton Park. The equipment includes a 300 and 30L New Brunswick fermentor, a Westfalia Centrifuge, a Certuss Steam generator and an Airco Pneumatics air compressor. The pilot plant will be used to optimise and demonstrate GBL's proprietary butanol fermentation process at scale on waste feedstocks.
Fergal O'Brien, Director of Process Operations comments "The pilot plant provides us with a facility to scale-up lab based processes. Demonstration at the 300 litres provides confidence to our feedstock partners and allows us to produce small amounts of butanol for testing purposes. We see this facility as a bridge between the lab and process demonstration at our partners facilities"
14.01.08
Appointment of Fergal O'Brien
GBL has appointed Fergal O'Brien Director of Process Operations. Fergal is a Biochemist with 25 years experience in the Biotechnology/ Fine Chemical Industry. He has held positions in R&D, operations, business development and senior management for a number of UK based companies including Celltech, Enzymatix, Chiroscience, Chirotech and Dow Pharmaceuticals; he was CEO of Warwick Effect Polymers Ltd from 2004-6. Fergal brings extensive experience in managing technical programmes and commercialising novel technologies and across the biotechnology sector.